Ulotaront

New York-based Definium Therapeutics, Inc. (Nasdaq: DFTX) announced a proposed underwritten public offering of USD 500 million in common shares and, to certain investors, pre-funded warrants, as it advances DT120 ODT toward potential approval and prepares for commercialization in psychiatric disorders. The capital raise reflects the cost burden of late-stage clinical development and pre-launch readiness activities for a psychedelic-derived compound navigating a regulatory pathway with limited precedent. The offering is structured as a primary issuance of common shares, with pre-funded warrants available in lieu of common shares to select investors. Underwriters have been granted a 30-day option to purchase up to an additional USD 75 million in shares at the public offering price, bringing the potential total to USD 575 million. Specific pricing and share count had not been disclosed at announcement. J.P. Morgan, Jefferies, Leerink Partners, and BofA Securities are acting as joint lead bookrunners, with Evercore ISI and Stifel as additional bookrunners. Definium stated proceeds will fund research and development of its pipeline, pre-commercialization preparation for DT120 ODT if approved, and general working capital. The offering is being made under an existing shelf registration statement. Company overview and pipeline Definium Therapeutics, headquartered in New York, is a late-stage clinical biopharmaceutical company applying a drug development framework to psychedelic compounds, with the stated aim of addressing the underlying neurobiological causes of psychiatric and neurological disorders. The company rebranded from MindMed to Definium Therapeutics in January 2026, signaling a shift in positioning toward a more conventional pharmaceutical identity as it approaches potential regulatory milestones. Its lead asset, DT120 ODT (lysergide D-tartrate), is an orally disintegrating tablet formulation of LSD developed using Catalent’s Zydis fast-dissolve platform, designed to optimize bioavailability and reduce gastrointestinal side effects. The molecule functions as a partial serotonin receptor agonist and is hypothesized to promote neural connectivity relevant to anxiety-related network dysregulation. DT120 ODT is being evaluated in two pivotal Phase III studies — Voyage and Panorama — for generalized anxiety disorder (GAD). Management has indicated topline data from Voyage is anticipated in Q2 2026, with Panorama results expected in the second half of 2026. The company has explicitly linked the current financing to preparation activities for a potential commercial launch of DT120 ODT, indicating management expects near-term regulatory submissions contingent on data outcomes. In the GAD competitive landscape, DT120 ODT faces potential competition from Sumitomo Pharma and Otsuka’s ulotaront (SEP-363856), a TAAR1 and 5-HT1A receptor agonist in Phase II/III development, and AbbVie’s ABBV-932, a selective dopamine D3-receptor modulator in clinical investigation for GAD as an add-on therapy. Current standard of care relies primarily on SSRIs, SNRIs, and buspirone, none of which address the same receptor targets as DT120 ODT, leaving mechanistic differentiation as a potential commercial argument if efficacy data are supportive. The USD 500 million offering size is consistent with the capital requirements of a company simultaneously running two registrational trials, building commercial infrastructure, and operating without product revenue. Comparable late-stage CNS and psychiatry-focused offerings in 2026 have ranged from USD 150 million to USD 500 million, with Xenon Pharmaceuticals’ USD 500 million offering in March 2026 representing a structurally similar transaction by a neuroscience-focused company at a comparable development stage. The offering’s outcome will depend materially on investor confidence in the Phase III data timeline and the regulatory receptivity to a psychedelic-derived compound in a mass-market psychiatric indication. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Copyright © 2026. AllSci Corp. All rights reserved.

Luye Pharma announced on April 8 that the first subject has been enrolled in the Phase II clinical trial in China of LY03020, an oral controlled-release tablet the company describes as a dual agonist targeting both TAAR1 and the serotonin 2C receptor, with the filing categorized under China’s Class 1 innovative drug designation for schizophrenia. The announcement, filed as a voluntary disclosure with the Hong Kong Stock Exchange, confirmed enrollment initiation only. Study design, patient population size, dosing regimen, primary endpoints, and blinding status were not disclosed in the source document. No safety or efficacy findings are available at this stage. The LY03020 China trial follows earlier IND clearance in both China and the United States, according to Luye Pharma’s prior disclosures, though no ClinicalTrials.gov registration for this specific Phase II China study was identified at the time of writing. The data remain unavailable pending trial progression, and no DSMB or monitoring statements were included in the announcement. The enrolled patient population, disease severity criteria, and trial duration have not been stated publicly. LY03020 is described by Luye Pharma as a small molecule dual agonist of TAAR1 and 5-HT2CR — a mechanistic profile that, if confirmed in clinical evaluation, would distinguish it from approved antipsychotics acting primarily through dopamine D2 receptor antagonism, such as risperidone, or the TAAR1-selective agonist ulotaront, which Sunovion advanced into Phase III before discontinuing development in 2023. TAAR1 agonism has been explored as a non-dopaminergic approach to schizophrenia, with the potential to avoid some adverse effects associated with D2 blockade, though clinical validation remains limited. Your email address will not be published. Required fields are marked * Comment * Name * Email * Website